Amifostine antioxidant effect on serum of rats treated with cyclophosphodamide

• Autorzy: Stankiewicz A , Skrzydlewska E.
• Języki publikacji: EN

Abstrakty

EN

Amifostine is one of the cytoprotective drugs used during anticancer therapy. Amifostine as a thiol compound possesses antioxidant properties and protects only healthy cells against damage, mainly by scavenging reactivity oxygen species, competing with oxygen to prevent oxygen radical interactions with DNA, and promoting cell repair through hydrogen donation to reactive oxygen species. The aim of the present study was to evaluate antioxidative ability of amifostine in blood serum of rats exposed to cyclophosphamide during two weeks after drug administration. We show that amifostine only to a small degree prevents disorganisation of antioxidant systems of blood serum of rats caused by cyclophosphamide action. It is probably connected with low concentrations of amifostine active metabolites in the serum.

Słowa kluczowe

EN

antioxidant effect; amifostine; blood serum; treatment; lipid peroxidation; rat; cyclophosphodamide

• Wydawca: -
• Czasopismo: Polish Journal of Environmental Studies
• Rocznik: 2005
• Tom: 14
• Numer: 3
• Opis fizyczny: p.341-346,ref.

Twórcy

autor

Stankiewicz A

• Medical Academy of Bialystok, P.O.Box 14, 15-230 Bialystok, Poland

autor

Skrzydlewska E.

Bibliografia

• 1. BONADONNA G., VALAGUSSA P., MOLITERNI A., ZAMBETTI M., BRAMBILLA C., Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer, N. Engl. J. Med., 332, 901, 1995.
• 2. MURPHY S. B., BOWMAN W. P., COOPER M. J., Results of treatment of advanced stage Burkitts lymphomas and B-cell (Sig+) acute lymphoblastic leukaemia with high dose fractionated cyclophosphamide and co-ordinated highdose methotrexate and cytarabine, J. Clin. Oncol., 4, 1732, 1986.
• 3. REITER A., ACHRAPPE M., LUDWIG W. D., HIDDEMANN W., SAUTER S., HENZE G., ZIMMERMANN M., LAMPERT F., HAVERS W., NIETHAMMER D., Chemotherapy in 998 unselected childhood acute lymphoblastic leucemia patients. Results and conclusions of the multicenter trial ALL-BFM 86, Blood, 84, 3122, 1994.
• 4. CAPIZZI R. L., Amifostine: the preclinical basis for broadspectrum selective cytoprotection of normal tissues from cytotoxic therapies, Semin. Oncol., 23, 2, 1996.
• 5. PARKE D. V., SAPOTA A., Chemical toxicity and reactive oxygen species, Int. J. Occup. Med. Env. Health., 9, 331, 1996.
• 6. SCHLEZINGER J., WHITE R. D., STEGEMAN J., Oxidative inactivation of cytochrome P450 1A (CYP1A) stimulated by 3,3’,4,4’-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1, As. Mol. Pharmacol., 56, 588, 1999.
• 7. KANEKAL S., KEHRER J. P., Metabolism of cyclophosphamide by lipooxygenases, Drug Metab. Disposition, 22, 74, 1994.
• 8. KANEKAL S., KEHRER J., Evidence for peroxidase-mediated metabolism of cyclophosphamide, Drug Metab. Disposition., 21, 37, 1993.
• 9. FRAISER L., KANEKAL S., KEHRER J. P., Cyclophosphamide toxicity: characterizing and avoiding the problem, Drugs, 42, 781, 1991.
• 10. LEVINE L. A., RICHIE J. P., Urological complications of cyclophosphamide. J. Urol. 141, 1063, 1989.
• 11. STANKIEWICZ A., SKRZYDLEWSKA E., Protection against cyclophosphamide-induced renal oxidative stress by amifostine: the role of antioxidative mechanisms, Toxicol. Mech. Methods., 13, 1, 2003.
• 12. CZEJKA M., SCHUELLER J., EDER I., REZNICEK G., KRAULE C., ZELENI U., FREITAG R., Clinical pharmacocinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine, Anticancer Res., 20, 3871, 2000.
• 13. DORR R. T., Cytoprotective agents for antracyclines, Semin. Oncol., 23, 23, 1996.
• 14. VAN der VIJGH W. J. F., KORST A. E. C., Amifostine (Ethyol): pharmacocinetic and pharmacodynamic effects in vivo, Eur. J. Cancer, 32, 26, 1996.
• 15. MISRA H. P., FRIDOVICH I., The role of superoxide anion in the autooxidation of epinefrine and a simple assay for superoxide dismutation, J. Biol. Chem., 247, 3170, 1972.
• 16. SYKES J. A., McCORMAC F. X., O`BREIEN T. J., Preliminary study of the superoxide dismutase content of some human tumors, Cancer Res., 38, 2759, 1978.
• 17. PAGLIA D. E., VALENTINE W. N., Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med., 70, 158, 1967.
• 18. MIZE C. E., LANGDON R. G., Hepatic glutathione reductase. I. Purification and general kinetic properties, J. Biol. Chem., 237, 1589, 1962.
• 19. TAKESHITA S., NAKATA R., TSUKAMOTO I., Change in the level vitamin C and lipid peroxidation in tissues of the inherently scorbutic rat during ascorbate deficiency, J. Argic. Food Chem., 44, 2748, 1996.
• 20. DELEENHERT A., DEBEVERE V., DERUTYER M. G., CLAEYS A. C. Simultaneus determination of retinol and αtokoferol in human serum by HPLC, J. Chromatogr., 162, 408, 1979.
• 21. YOSHINO K., MATSURA T., SANO M. Fluorometric lipid chromatographic determination of aliphatic aldehydes arising from lipid peroxides, Chem. Pharm. Bull., 34, 1694, 1986.
• 22. LONDERO D., GRECO P. L., Automated HPLC separation with spectrofluorometric detection of malondialdehydethiobarbituric acid adduct in plasma, J. Chromatogr. A., 729, 207, 1996.
• 23. MYERS C. E., Anthrocyclines. ed.; Pharmacologic Principles of Cancer Treatment: Philadelphia, pp 416-434, 1982.
• 24. REED E., OZOLS R. F., TARONE R., Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum – based chemotherapy. Proc. Natl. Acad. Sci. USA, 84, 5024, 1987.
• 25. MATES J. M, PEREZ-GOMEZ C., NUNEZ de CASTRO. I., Antioxidant enzymes and human diseases, Clin. Biochem., 32, 595, 1999.
• 26. BEERY C., ANDERSON N., KIRK A. J., DOMINICZAK A. F., McMURRAYAND J. J., Renin angiotensin system inhibition is associated with reduced free radical concentration in arteries of patients with coronary heart disease, Heart, 86, 217, 2001.
• 27. SIEMS W., QUAST S., CARLUCCIO F., WISWEDEL I., HIRSCH D., AUGUSTIN W., HAMPL H., RIEHLE M., SOMMERBURG O., Oxidative stress in chronic renal failure as a cardiovascular risk factor, Clin. Nephrol., 58, S12, 2002.
• 28. DURKEN M., AGBENU J., FINCKH B., HUBNER C., PICHLMEIER U., ZELLER W., WINKLER K., ZANDER A., KOHLSCHUTTER A., Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation, Bonne Marrow Transplant., 15, 7570, 1995.
• 29. FRIDOVICH I., FREEMAN B., Antioxidant defenses in the lung, Ann. Rev. Physiol., 48, 693, 1986.
• 30. GILBERT H., Redox control of enzyme activities by thiol/ disulfide exchange, Method Enzymol., 107, 330, 1984.
• 31. UCHIDA K., KANEMATSU M., SAKAI K., MATSUDA T., HATTORI N., MIZUNO Y., SUZUKI D., MIYATA T., NOGUCHI N., NIKI E., OSAWA T., Protein-bound acrolein: potential markers for oxidative stress, Proc. Natl. Acad. Sci., 95, 4882, 1998.
• 32. RAMU K., FRAISER L. H., MAMIYA B., Acrolein mercapturates: synthesis, characterization and assessment of their role in the bladder toxicity of cyclophosphamide, Chem. Res. Toxicol., 8, 515, 1995.
• 33. HAENEN G.R., VERMEULEN N. P., TAI TIN TSOI J. N., RAGETI H.M., TIMMERMAN H., BLAST A., Activation of the microsomal glutathione S transferase and reduction of the glutathione dependent protection against lipid peroxidation by acrolein, Biochem. Pharmacol., 37, 1933, 1998.
• 34. BURTON G. W., INGOID K. U., Vitamin E as an in vitro and in vivo antioxidant, Ann. NY Acad. Sci., 570, 72, 1989.
• 35. CHOW C. K., Vitamin E and oxidative stress, Free Radic. Biol. Med. 11, 215, 1991.
• 36. LEE I. M., Antioxidant vitamins in prevention of cancer, Proc. Assoc. Am. Physicians., 111, 1, 1999.
• 37. BRIZEL D. M., Future directions in toxicity prevention, Semin. Radiat. Oncol., 8, 17, 1998.
• 38. LEWIS C., A review of the use of chemoprotectants in cancer chemotherapy, Drug Safety, 11, 153, 1994.
• 39. SCHUCHTER L. M., Current role of protective agents in cancer treatment, Oncology, 11, 505, 1997.
• 40. DOUAY L., HU C., GIARRATANA M. C., Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants, Semin. Oncol., 21, 16, 1994.
• 41. FRIEDMAN H. S., COLVIN O. M., AISAKA K., POPP J., BOSSEN E. H., REIMER K. A., POMELL J. B., HILTON J., GROSS S. S., LEVI R., Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity, Cancer Res., 50, 2455, 1990.
• 42. VENKATESAN N., CHANDRAKASAN G., Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant, Mol. Cell Biol., 142, 79, 1995.
• 43. GRDINA D. J., KATAOKA Y., MURLEY J. S., Amifostine: mechanisms of action underlying cytoprotection and chemoprevention, Drug Metab. Drug Interact., 16, 237, 2000.
• 44. MARZATICO F., PORTA C., MORONI M., BERTORELLI L., BORASIO E., FINOTTI N., PANSARASA O., CASTAGNA L., In vitro antioxidant properties of amifostine (WR-2721, Ethol), Cancer Chemother. Pharmacol., 45, 172, 2000.
• 45. OHNISHI S. T., OHNISHI T., GLICK J. H., SCHEIN P. S., In vitro study on the antioxidant activities of amifostine (WR-2721), Proc. Am. Assoc. Cancer Res., 33, 419a, 1992.
• 46. ORDITURA M., DeVITA F., ROSCIGNO A., Amifostine: a selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity, Oncol. Rep., 6, 1357, 1999.
• 47. SHAW L. M., BONNER H. S., SCHUCHTER L., SCHILLER J., LIEBERMAN R., Pharmacokinetics of amifostine: effects of dose and method of administration, Semin. Oncol., 26, 34, 1999.
• 48. SHAW L. M., BONNER H. S., BROWN D. Q., Metabolic pathways of WR-2721 (ethol, amifostine) in the BALB/c mause, Drug Metab. Dispos., 22, 895, 1994.
• 49. STANKIEWICZ A., SKRZYDLEWSKA E., MAKIEŁA M., Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats, Drug Metab. Drug Interact., 19, 67, 2002.
• 50. STANKIEWICZ A., SKRZYDLEWSKA E., SULKOWSKA M., SULKOWSKI S., Effect of amifostine on lung oxidative stress after cyclophosphamide therapy, Bull. Vet. Pulawy, 46, 87, 2002.